Celgene's US $50 million cooperation with Juno to deepen the R & D cooperation of car-t treatment

Source: Biovalley 2016-04-12 recently, celgene and Juno reached a car-t R & D cooperation targeting CD19, with a transaction amount of US $50 million According to the agreement, celgene will obtain the R & D and commercialization rights of the project outside Europe, North America and China, while Juno still reserves the commercialization rights in North America and China In June last year, celgene and Juno reached a 10-year, $1 billion global cooperation R & D agreement on car-t to enter the field of tumor immunity Car-t, also known as chimeric antigen receptor T-cell therapy, refers to the immunotherapy that enables T cells to express antibodies that recognize specific tumor surface antigens through gene engineering and cell engineering methods, so as to kill tumor efficiently and specifically Juno is a pioneer in tumor immunotherapy, especially in car-t Since its establishment, the company has been the backbone of the industry for less than two years, creating a miracle in the industry Juno currently has three car-t treatment projects targeting CD19 under research, namely jcar015, jcar017 and jcar014 Jcar015 is currently in phase II clinical trial stage of adult relapsed / refractory acute lymphoblastic leukemia; jcar017 is in phase I clinical trial stage of children's acute lymphoblastic leukemia and non Hodgkin's lymphoma Jcar014 is in phase I clinical trial in three indications, namely, adult acute lymphocytic leukemia, non Hodgkin lymphoma and chronic lymphocytic leukemia In addition, jcar014 was used in combination with durvalumab, a PD-L1 inhibitor of AstraZeneca This cooperation will help celgene to further strengthen its position in the field of car-t treatment, currently the strong competitors in this field are Novartis and kite pharmaceutical Hans bishop, CEO of Juno, said celgene was very professional in R & D and commercialization, especially in the field of blood tumor diseases Working with celgene will help Juno strengthen its R & D and commercialization capabilities in the fields of acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non Hodgkin's lymphoma, etc The long-term cooperation with celgene is an important part of Juno's development of car-t treatment platform, which is conducive to the rapid benefit of blood tumor patients all over the world.